Nexvet Biopharma plc·4

Aug 2, 9:25 PM ET

Gunn George W 4

4 · Nexvet Biopharma plc · Filed Aug 2, 2017

Insider Transaction Report

Form 4
Period: 2017-07-31
Transactions
  • Disposition to Issuer

    Ordinary Shares

    2017-07-31$6.72/sh42,600$286,2720 total
  • Disposition to Issuer

    Restricted Share Units

    2017-07-31$6.59/sh1,500$9,8930 total
    Exercise: $0.13Exp: 2019-07-01Ordinary Shares (1,500 underlying)
Footnotes (2)
  • [F1]Disposed of pursuant to a transaction agreement between the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired the Issuer.
  • [F2]This restricted share unit, which would have vested and become convertible as to 500 shares on each of 9/30/17, 12/31/17 and 3/31/18, in each case subject to payment of the nominal value per share of $0.125 to the Issuer within 30 days of vesting, was cancelled in the Acquisition in exchange for a cash payment equal to $9,892.50. This amount represents the difference between such nominal value per share and the $6.72 consideration per share payable in connection with in the Acquisition, multiplied by the number of shares issuable on conversion of the restricted share unit.

Documents

1 file
  • 4
    edgar.xmlPrimary

    PRIMARY DOCUMENT